These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17965736)

  • 1. Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome.
    Takemasa H; Nagatomo T; Abe H; Kawakami K; Igarashi T; Tsurugi T; Kabashima N; Tamura M; Okazaki M; Delisle BP; January CT; Otsuji Y
    Br J Pharmacol; 2008 Feb; 153(3):439-47. PubMed ID: 17965736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
    Rajamani S; Eckhardt LL; Valdivia CR; Klemens CA; Gillman BM; Anderson CL; Holzem KM; Delisle BP; Anson BD; Makielski JC; January CT
    Br J Pharmacol; 2006 Nov; 149(5):481-9. PubMed ID: 16967046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
    Han S; Zhang Y; Chen Q; Duan Y; Zheng T; Hu X; Zhang Z; Zhang L
    Eur J Pharmacol; 2011 Jan; 650(1):138-44. PubMed ID: 20951697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
    Kikuchi K; Nagatomo T; Abe H; Kawakami K; Duff HJ; Makielski JC; January CT; Nakashima Y
    Br J Pharmacol; 2005 Mar; 144(6):840-8. PubMed ID: 15778703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
    Jehle J; Ficker E; Wan X; Deschenes I; Kisselbach J; Wiedmann F; Staudacher I; Schmidt C; Schweizer PA; Becker R; Katus HA; Thomas D
    Br J Pharmacol; 2013 Mar; 168(5):1215-29. PubMed ID: 23061993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.
    Kawakami K; Nagatomo T; Abe H; Kikuchi K; Takemasa H; Anson BD; Delisle BP; January CT; Nakashima Y
    Br J Pharmacol; 2006 Mar; 147(6):642-52. PubMed ID: 16314852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propofol inhibits hERG K
    Han SN; Jing Y; Yang LL; Zhang Z; Zhang LR
    Eur J Pharmacol; 2016 Nov; 791():168-178. PubMed ID: 27575519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of a novel anti-arrhythmic drug, acehytisine hydrochloride, on the human ether-a-go-go related gene K channel and its trafficking.
    Huang X; Yang Y; Zhu J; Dai Y; Pu J
    Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):145-54. PubMed ID: 19143746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656.
    Ridley JM; Milnes JT; Duncan RS; McPate MJ; James AF; Witchel HJ; Hancox JC
    FEBS Lett; 2006 Apr; 580(8):1999-2005. PubMed ID: 16542653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
    Ficker E; Obejero-Paz CA; Zhao S; Brown AM
    J Biol Chem; 2002 Feb; 277(7):4989-98. PubMed ID: 11741928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs.
    Bai YL; Liu HB; Sun B; Zhang Y; Li Q; Hu CW; Zhu JX; Gong DM; Teng X; Zhang Q; Yang BF; Dong DL
    J Mol Cell Cardiol; 2011 Nov; 51(5):876-80. PubMed ID: 21820442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
    Obers S; Staudacher I; Ficker E; Dennis A; Koschny R; Erdal H; Bloehs R; Kisselbach J; Karle CA; Schweizer PA; Katus HA; Thomas D
    Naunyn Schmiedebergs Arch Pharmacol; 2010 May; 381(5):385-400. PubMed ID: 20229012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of HERG and Kv1.5 by ketoconazole.
    Dumaine R; Roy ML; Brown AM
    J Pharmacol Exp Ther; 1998 Aug; 286(2):727-35. PubMed ID: 9694927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HERG-F463L potassium channels linked to long QT syndrome reduce I(Kr) current by a trafficking-deficient mechanism.
    Yang HT; Sun CF; Cui CC; Xue XL; Zhang AF; Li HB; Wang DQ; Shu J
    Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):822-7. PubMed ID: 19215240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockage of hERG current and the disruption of trafficking as induced by roxithromycin.
    Han SN; Yang SH; Zhang Y; Duan YY; Sun XY; Chen Q; Fan TL; Ye ZK; Huang CZ; Hu XJ; Zhang Z; Zhang LR
    Can J Physiol Pharmacol; 2013 Dec; 91(12):1112-8. PubMed ID: 24289083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction with GM130 during HERG ion channel trafficking. Disruption by type 2 congenital long QT syndrome mutations. Human Ether-à-go-go-Related Gene.
    Roti EC; Myers CD; Ayers RA; Boatman DE; Delfosse SA; Chan EK; Ackerman MJ; January CT; Robertson GA
    J Biol Chem; 2002 Dec; 277(49):47779-85. PubMed ID: 12270925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
    Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
    Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L; Wible BA; Wan X; Ficker E
    J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.
    Hancox JC; Mitcheson JS
    Br J Pharmacol; 2006 Nov; 149(5):457-9. PubMed ID: 16967047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes.
    Guo J; Massaeli H; Li W; Xu J; Luo T; Shaw J; Kirshenbaum LA; Zhang S
    J Pharmacol Exp Ther; 2007 Jun; 321(3):911-20. PubMed ID: 17377062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.